Want to see CATX full AI Analyst Report?
CATX Stock Chart & Stats
$4.20
-$0.13(-3.36%)
At close: 4:00 PM EST
$4.20
-$0.13(-3.36%)
Day’s Range― - ―
52-Week Range$1.96 - $6.16
Previous CloseN/A
Volume311.62K
Average Volume (3M)2.13M
Market Cap
$331.87M
Enterprise Value$165.33
Total Cash (Recent Filing)$270.93M
Total Debt (Recent Filing)$4.23M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Aug 18, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-26.44
Shares Outstanding114,046,196
10 Day Avg. Volume1,696,138
30 Day Avg. Volume2,126,232
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio-2.13
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.33Price Target Upside217.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.1
Revenue Forecast (FY)$397.03K
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExceptionally low leverage and sizable equity provide durable financial flexibility for a clinical-stage biotech. This reduces refinancing risk, supports multi-year R&D and manufacturing investments, and allows the company to fund trials and build capacity without immediate debt pressure, preserving strategic optionality.
Clinical Program MomentumConsistent efficacy and tolerability across three 212Pb programs (neuroendocrine, melanoma, FAP-α solid tumors) materially de-risks development pathways. Durable responses and manageable safety profiles increase the chance of registration-enabling studies and broaden commercial opportunity over the medium term.
Vertical Manufacturing BuildoutInvesting in end-to-end, regional manufacturing and direct-to-hospital delivery creates a defensible operational advantage for short‑lived isotopes. Owning supply chain reduces reliance on third parties, supports reliable product availability, and strengthens commercialization readiness and potential margin capture post-approval.
Bears Say
Very Weak Revenue And Large LossesCurrent operating performance is deeply negative: minimal revenue with very large recurring losses means the business model is not yet generating cash or profits. Absent successful clinical readouts or commercialization, this dynamic can persist for multiple quarters, delaying value realization for investors.
High Cash BurnSustained, large negative operating and free cash flows imply ongoing reliance on external financing or the existing cash stockpile. Even with recent equity raises, continued high R&D and buildout spending can compress runway and necessitate future capital raises, diluting shareholders and adding execution risk.
Negative Returns On CapitalA materially negative ROE indicates the company’s substantial equity base is not producing returns today. If losses persist through development and manufacturing scale-up, the capital base can be eroded and investor patience tested, meaning achieving profitable operations is a critical structural hurdle.
Perspective Therapeutics News
CATX FAQ
What was Perspective Therapeutics, Inc.’s price range in the past 12 months?
Perspective Therapeutics, Inc. lowest stock price was $1.96 and its highest was $6.16 in the past 12 months.
What is Perspective Therapeutics, Inc.’s market cap?
Perspective Therapeutics, Inc.’s market cap is $331.87M.
When is Perspective Therapeutics, Inc.’s upcoming earnings report date?
Perspective Therapeutics, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 22 days.
How were Perspective Therapeutics, Inc.’s earnings last quarter?
Perspective Therapeutics, Inc. released its earnings results on May 11, 2026. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.294 by $0.044.
Is Perspective Therapeutics, Inc. overvalued?
According to Wall Street analysts Perspective Therapeutics, Inc.’s price is currently Undervalued.
Does Perspective Therapeutics, Inc. pay dividends?
Perspective Therapeutics, Inc. does not currently pay dividends.
What is Perspective Therapeutics, Inc.’s EPS estimate?
Perspective Therapeutics, Inc.’s EPS estimate is -0.25.
How many shares outstanding does Perspective Therapeutics, Inc. have?
Perspective Therapeutics, Inc. has 114,046,196 shares outstanding.
What happened to Perspective Therapeutics, Inc.’s price movement after its last earnings report?
Perspective Therapeutics, Inc. reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.294. Following the earnings report the stock price went down -2.835%.
Which hedge fund is a major shareholder of Perspective Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CATX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Perspective Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.33 (217.46% Upside)
$13.33 (217.46% Upside)
Blogger Sentiment
Bullish
CATX Sentiment 70%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 80.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
24.72%
Trailing 12-Months
Company Description
Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
CATX Stock 12 Month Forecast
Average Price Target
$13.33
▲(217.46% Upside)
Technical Analysis
Ownership Overview
1.63% Insiders
6.91% Mutual Funds
0.12% Other Institutional Investors
77.29% Public Companies and
Individual Investors